Latest News

Mesothelioma Support Coordinator

Jocelyn McLean joins the Asbestos Diseases Research Institute (ADRI), after many years of caring for patients having surgery for lung cancer, mesothelioma and benign conditions at Royal Prince Alfred Hospital. Utilising her knowledge and experience of patient and carer needs and drawing from current survivorship research and carer need research…

Read More

Patient study: Quality of life

Quality of life in patients with Mesothelioma The ADRI is running a study investigating ‘quality of life’ in patients diagnosed with mesothelioma. While we are aware that there is a high symptom burden in patients suffering from mesothelioma, we have little information on ‘quality of life’ in people living with…

Read More

ADRI Research recognised by award at WIN Symposium

The research leading to ADRI’s upcoming clinical trial has been recognised by the award of one of two best poster prizes at the recent WIN Symposium 2014 in Paris. The study describes the translational research leading to the new microRNA-based treatment approach for malignant pleural mesothelioma and non-small cell lung…

Read More

Dr Glen Reid receives grant from the Cancer Council NSW

Following on from last year’s breakthrough research into the role of microRNAs in malignant pleural mesothelioma, Dr Glen Reid has been awarded a $346,000 grant from the Cancer Council NSW to further ADRI’s research into microRNA-based replacement therapy. One of just 16 applications funded this year, the project entitled “Developing…

Read More

Dr Steven Kao, clinical research fellow

Dr Steven Kao is a medical oncologist at the Chris O’Brien Lifehouse, Camperdown. He completed his PhD at the ADRI and focused his research on predictive and prognostic factors in malignant mesothelioma. Steven has a wide clinical, translational and psycho-social research interest in thoracic cancers including malignant mesothelioma and asbestos-related…

Read More

PhD Scholarships – Mesothelioma Research

The Asbestos Diseases Research Institute (ADRI) is located on the Concord Hospital campus under the leadership of Professor Ken Takahashi – is the world’s first stand-alone research facility dedicated to the prevention and treatment of asbestos-related diseases, particularly malignant mesothelioma. Australia has the highest incidence of mesothelioma in the world with around…

Read More
Victoria Keena

Victoria Keena, executive officer

Victoria Keena joined the ADRI in August 2008 as a Senior Consultant after many years as the General Manager of the Woolcock Institute of Medical Research. Victoria assisted with fitout and development of the ADRI since it opened in January 2009. She has had extensive hands-on experience in the administration…

Read More

Ross Flemons, accountant

Ross Flemons joined the ADRI in December 2009 as part time Accountant. His previous position was as Finance Manager at the Woolcock Institute of Medical Research where he worked for 14 years. Ross is CPA qualified and has vast experience with all financial matters relating to independent medical research organisations,…

Read More
Marissa Williams

Marissa Williams, PhD student

Marissa Williams commenced work at ADRI in February 2012 as a research assistant, and began her PhD studies in 2015. She completed her undergraduate degree of Forensic Biology in Biomedical Science at the University of Technology Sydney and went on to undertake an honours project in paediatric oncology at the…

Read More

New research results show deadly asbestos-related cancer slowed down

Australian scientists, inventors and surgeons worked together in ground-breaking research that has lead to the discovery of a way to slow down the growth of deadly asbestos-related cancer malignant pleural mesothelioma. The break-through underpins a clinical trial due to start in six weeks.

More than 10,000 Australians have died since the early 1980s, with more than 25,000 expected to die over the next four decades, because of mesothelioma, an asbestos-related cancer. The cancer can take up to 40 years to develop.

Read More